BD Hypak™ for Vaccines Glass Prefillable Syringe System
BD tools for vaccine combination product developers
- Overview
- Expertise
- Availability
- Products & Accessories
- Resources
BD HypakTM for Vaccines Glass Prefillable Syringe System selected by the top 5 vaccine pharmaceutical companies1 2:
- key specifications are adapted to the current needs of vaccine manufacturing.3
- minimized risk of deviation through In-Process Controls implemented at critical steps of the manufacturing process.3
BD HypakTM for Vaccines Glass Prefillable Syringe Features
- Flange optimal resistance2
- Prevents rolling*
BD HypakTM for Vaccines Glass Prefillable Syringe Benefits
- Key specifications adapted to the current needs of vaccine manufacturing3
- Minimized risk of deviation through In-Process Controls implemented at critical steps of the manufacturing process3
- Multi-sourcing network for business continuity
- 30 reference available: staked needle or luer tip, different flanges, tip or needle caps, etc.
* BD tools for vaccine combination product developers.
- Market analysis and product sales for Vaccines, from 2014 to 2018 [internal analysis]. Pont de Claix, FR: Becton, Dickinson and Company; 2019
- Vaccines Market Leaders, https://www.statista.com/statistics/314562/leading-global-pharmaceuticalcompanies-by-vaccine-revenue/ accessed 4th April 2018
- BD HypakTM for vaccines needle design verification rationale [internal study]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2013
Our expertise in BD HypakTM for Vaccines Glass Prefillable Syringe
- Nearly 3 billion units sold since launch4
- Selected by the top 5 vaccine pharmaceutical companies 1,2
- BD is uniquely positioned with high volume production capacity delivering hundreds of millions4 of BD HypakTM for Vaccines each year
- Market analysis and product sales for Vaccines, from 2014 to 2018 [internal analysis]. Pont de Claix, FR: Becton, Dickinson and Company; 2019
- Vaccines Market Leaders, https://www.statista.com/statistics/314562/leading-global-pharmaceuticalcompanies-by-vaccine-revenue/ accessed 4th April 2018
- BD HypakTM for vaccines needle design verification rationale [internal study]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2013
- BD sales analysis [internal analysis]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2019
- BD-PS external communication to customers - BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years https://news.bd.com/2020-12-02-BD-to-Invest-1-2-Billion-in-Pre-Fillable-Syringe-Manufacturing-Capacity-Over-Next-Four-Years/Accessed Dec. 2, 2020
- Will benefit from BD long-term capacity extension program with investment of over USD 1.2 billion for ready-to-administer containers for injectable drugs1
- Samples available on demand
- Commercial availability to be evaluated against requirements.
- BD-PS external communication to customers - BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years https://news.bd.com/2020-12-02-BD-to-Invest-1-2-Billion-in-Pre-Fillable-Syringe-Manufacturing-Capacity-Over-Next-Four-Years/Accessed Dec. 2, 2020
Literature
View collected literature about BD offerings and our industry for information you can use to continue striving for excellence.
Learn more